You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

PEXEVA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Pexeva patents expire, and when can generic versions of Pexeva launch?

Pexeva is a drug marketed by Sebela Ireland Ltd and is included in one NDA. There is one patent protecting this drug.

This drug has forty patent family members in twenty-five countries.

The generic ingredient in PEXEVA is paroxetine mesylate. There are thirty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the paroxetine mesylate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Pexeva

A generic version of PEXEVA was approved as paroxetine mesylate by ACTAVIS LABS FL INC on June 20th, 2017.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for PEXEVA?
  • What are the global sales for PEXEVA?
  • What is Average Wholesale Price for PEXEVA?
Summary for PEXEVA
Drug patent expirations by year for PEXEVA
Drug Prices for PEXEVA

See drug prices for PEXEVA

Drug Sales Revenue Trends for PEXEVA

See drug sales revenues for PEXEVA

Recent Clinical Trials for PEXEVA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sheppard Pratt Health SystemN/A
Central Michigan UniversityN/A

See all PEXEVA clinical trials

US Patents and Regulatory Information for PEXEVA

PEXEVA is protected by one US patents.

Patents protecting PEXEVA

Crystalline paroxetine methane sulfonate
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-001 Jul 3, 2003 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-004 Jul 3, 2003 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-002 Jul 3, 2003 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-003 Jul 3, 2003 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PEXEVA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-002 Jul 3, 2003 ⤷  Sign Up ⤷  Sign Up
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-001 Jul 3, 2003 ⤷  Sign Up ⤷  Sign Up
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-004 Jul 3, 2003 ⤷  Sign Up ⤷  Sign Up
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-002 Jul 3, 2003 ⤷  Sign Up ⤷  Sign Up
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-003 Jul 3, 2003 ⤷  Sign Up ⤷  Sign Up
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-001 Jul 3, 2003 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for PEXEVA

See the table below for patents covering PEXEVA around the world.

Country Patent Number Title Estimated Expiration
Estonia 03970 4-fenüülpiperidiinühend, selle valmistamine ja kasutamine ning seda sisaldav ravim ⤷  Sign Up
Estonia 9900570 ⤷  Sign Up
South Korea 20010013615 ⤷  Sign Up
Hong Kong 1027352 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 9856787 ⤷  Sign Up
Norway 20042101 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.